Emergent Biosolutions Stock News

Qiagen (QGEN) delivered earnings and revenue surprises of 12.68% and 6.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

In early 2021, in the eye of the Covid storm, there was a mix-up in the manufacturing of the Covid-19 vaccine developed by Johnson & Johnson ( JNJ , Financial) and manufactured by the contractor Emerg

GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial

GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial r

GAITHERSBURG, Md., March 23, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its board of directors (the “board”) has undertaken a series of changes consiste

GAITHERSBURG, Md., March 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the followi

GAITHERSBURG, Md., March 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following i

Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.

NEW YORK , March 14, 2022 /PRNewswire/ -- Polaris Market Research recently published a research report on "Sleeping Aids Market Share, Size, Trends, Industry Analysis Report, By Product (Mattresses & Pillows, Sleep Laboratories, Medications, Sleep Apnea Devices); By Sleep Disorders; By Region; Segment Forecast, 2022 - 2030" in its research database. According to research report published by Polaris Market Research, the global Sleeping Aids Market size expected to reach to USD 118.31 Billion by 2030 from USD 64.08 Billion in 2021, at a compound annual growth rate (CAGR) of 7.1% during forecast period 2022 to 2030. Report Overview: Sleeping aids products are used in the form of medicines and medical devices to ensure proper monitoring, diagnosis, and treatment for sleep disturbances and disorders. Symptoms of sleep disorders include excessive daytime sleepiness, irregular breathing, or increased movement during sleep. Sleep disorders causes problems with the quality, timing, and amount of sleep, which result in irregular breathing and abnormal sleeping behaviors.

Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.

Emergent BioSolutions (EBS) dosed the first person in a phase 1 trial of stabilized isoamyl nitrite ((SIAN)) to treat known or suspected acute cyanide poisoning.Under an…

AVVIY, EBS, and NVEI have been added to the Zacks Rank #5 (Strong Sell) List on March 11, 2022.

GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tole

AVVIY, EBS, and NVEI have been added to the Zacks Rank #5 (Strong Sell) List on March 11, 2022.

Presented by Emergent BioSolutions…